BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hurst DP, Garai S, Kulkarni PM, Schaffer PC, Reggio PH, Thakur GA. Identification of CB1 Receptor Allosteric Sites Using Force-Biased MMC Simulated Annealing and Validation by Structure-Activity Relationship Studies. ACS Med Chem Lett 2019;10:1216-21. [PMID: 31413808 DOI: 10.1021/acsmedchemlett.9b00256] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Leo LM, Al-zoubi R, Hurst DP, Stephan AP, Zhao P, Tilley DG, Miess E, Schulz S, Abood ME, Reggio PH. The NPXXY Motif Regulates β-Arrestin Recruitment by the CB1 Cannabinoid Receptor. Cannabis and Cannabinoid Research. [DOI: 10.1089/can.2021.0223] [Reference Citation Analysis]
2 Gado F, Ceni C, Ferrisi R, Sbrana G, Stevenson LA, Macchia M, Pertwee RG, Bertini S, Manera C, Ortore G. CB1 receptor binding sites for NAM and PAM: A first approach for studying, new n‑butyl‑diphenylcarboxamides as allosteric modulators. Eur J Pharm Sci 2021;169:106088. [PMID: 34863873 DOI: 10.1016/j.ejps.2021.106088] [Reference Citation Analysis]
3 Garai S, Schaffer PC, Laprairie RB, Janero DR, Pertwee RG, Straiker A, Thakur GA. Design, synthesis, and pharmacological profiling of cannabinoid 1 receptor allosteric modulators: Preclinical efficacy of C2-group GAT211 congeners for reducing intraocular pressure. Bioorg Med Chem 2021;50:116421. [PMID: 34634617 DOI: 10.1016/j.bmc.2021.116421] [Reference Citation Analysis]
4 Leo LM, Abood ME. CB1 Cannabinoid Receptor Signaling and Biased Signaling. Molecules 2021;26:5413. [PMID: 34500853 DOI: 10.3390/molecules26175413] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
5 Zagzoog A, Brandt AL, Black T, Kim ED, Burkart R, Patel M, Jin Z, Nikolaeva M, Laprairie RB. Assessment of select synthetic cannabinoid receptor agonist bias and selectivity between the type 1 and type 2 cannabinoid receptor. Sci Rep 2021;11:10611. [PMID: 34012003 DOI: 10.1038/s41598-021-90167-w] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
6 Garai S, Leo LM, Szczesniak AM, Hurst DP, Schaffer PC, Zagzoog A, Black T, Deschamps JR, Miess E, Schulz S, Janero DR, Straiker A, Pertwee RG, Abood ME, Kelly MEM, Reggio PH, Laprairie RB, Thakur GA. Discovery of a Biased Allosteric Modulator for Cannabinoid 1 Receptor: Preclinical Anti-Glaucoma Efficacy. J Med Chem 2021;64:8104-26. [PMID: 33826336 DOI: 10.1021/acs.jmedchem.1c00040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
7 Saldaña-Shumaker SL, Grenning AJ, Cunningham CW. Modern approaches to the development of synthetic cannabinoid receptor probes. Pharmacol Biochem Behav 2021;203:173119. [PMID: 33508249 DOI: 10.1016/j.pbb.2021.173119] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
8 Aderibigbe AO, Pandey P, Doerksen RJ. Negative allosteric modulators of cannabinoid receptor 1: Ternary complexes including CB1, orthosteric CP55940 and allosteric ORG27569. J Biomol Struct Dyn 2021;:1-19. [PMID: 33480332 DOI: 10.1080/07391102.2021.1873187] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Wu T, Jia J, Luo W, Bian H, Tang H, Pan Y, Huang F. A robust heterogeneous Co-MOF catalyst in azide–alkyne cycloaddition and Friedel–Crafts reactions as well as hydrosilylation of alkynes. New J Chem 2021;45:872-80. [DOI: 10.1039/d0nj04626d] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
10 Schaffer PC, Kulkarni PM, Janero DR, Thakur GA. Focused structure-activity relationship profiling around the 2-phenylindole scaffold of a cannabinoid type-1 receptor agonist-positive allosteric modulator: site-III aromatic-ring congeners with enhanced activity and solubility. Bioorg Med Chem 2020;28:115727. [PMID: 33065437 DOI: 10.1016/j.bmc.2020.115727] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Morales P, Jagerovic N. Novel approaches and current challenges with targeting the endocannabinoid system. Expert Opin Drug Discov 2020;15:917-30. [PMID: 32336154 DOI: 10.1080/17460441.2020.1752178] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
12 Garai S, Kulkarni PM, Schaffer PC, Leo LM, Brandt AL, Zagzoog A, Black T, Lin X, Hurst DP, Janero DR, Abood ME, Zimmowitch A, Straiker A, Pertwee RG, Kelly M, Szczesniak AM, Denovan-Wright EM, Mackie K, Hohmann AG, Reggio PH, Laprairie RB, Thakur GA. Application of Fluorine- and Nitrogen-Walk Approaches: Defining the Structural and Functional Diversity of 2-Phenylindole Class of Cannabinoid 1 Receptor Positive Allosteric Modulators. J Med Chem 2020;63:542-68. [PMID: 31756109 DOI: 10.1021/acs.jmedchem.9b01142] [Cited by in Crossref: 20] [Cited by in F6Publishing: 27] [Article Influence: 10.0] [Reference Citation Analysis]
13 Tkachenko V, Farafonov V, Tokarev V, Tkachenko I. Study of the effectiveness of various cannabinoid receptor 1 (CB1) agonists using molecular docking and molecular dynamics modeling. Fr Ukr J Chem 2020;8:76-87. [DOI: 10.17721/fujcv8i1p76-87] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Vanden Eynde JJ, Mangoni AA, Rautio J, Leprince J, Azuma YT, García-Sosa AT, Hulme C, Jampilek J, Karaman R, Li W, Gomes PAC, Hadjipavlou-Litina D, Capasso R, Geronikaki A, Cerchia L, Sabatier JM, Ragno R, Tuccinardi T, Trabocchi A, Winum JY, Luque FJ, Prokai-Tatrai K, Spetea M, Gütschow M, Kosalec I, Guillou C, Vasconcelos MH, Kokotos G, Rastelli G, de Sousa ME, Manera C, Gemma S, Mangani S, Siciliano C, Galdiero S, Liu H, Scott PJH, de Los Ríos C, Agrofoglio LA, Collina S, Guedes RC, Muñoz-Torrero D. Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes-6. Molecules 2019;25:E119. [PMID: 31905602 DOI: 10.3390/molecules25010119] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
15 Laprairie RB, Mohamed KA, Zagzoog A, Kelly MEM, Stevenson LA, Pertwee R, Denovan-Wright EM, Thakur GA. Indomethacin Enhances Type 1 Cannabinoid Receptor Signaling. Front Mol Neurosci 2019;12:257. [PMID: 31680861 DOI: 10.3389/fnmol.2019.00257] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]